MRTX-1257 is primarily investigated for its potential in cancer therapy, particularly targeting specific genetic mutations that drive tumor growth. It is being studied as a selective inhibitor of KRAS G12C, a mutation commonly found in various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer. By inhibiting this mutation, MRTX-1257 aims to disrupt the signaling pathways that promote cancer cell proliferation and survival, offering a targeted treatment option for patients with these mutations. Its application is significant in precision medicine, where therapies are tailored to the genetic profile of individual tumors, potentially improving outcomes and reducing side effects compared to traditional chemotherapy.